Navigation Links
Scientific and Business Leaders to Discuss Challenges Facing Developers of Pain Therapeutics at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:5/25/2010

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics.

Minneapolis, MN (PRWEB) May 25, 2010 -- The Agenda for Arrowhead’s 4th Annual Pain Therapeutics Summit, set to take place on October 4th-5th, 2010 in Philadelphia, has been announced.

Now in its 4th year, Arrowhead's Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics.

Topics covered at this year’s Summit include:

Regulatory hurdles in pain drug development
Animal models for pain drug discovery research
Clinical development models
Trial Designs
Abuse-deterrent opioids
Long-term opioid use
Next generation therapeutics for pain
Trends in pain drug development
Preclinical and clinical activity in pain space
FDA Update
Market direction of the field of pain therapeutics
Translational pain research
Competitive landscape
Mixing basic science, drug development and clinical practice
Discovery targets: TRPV, TRPA, TRPM8, NGF antagonists, Nav1.7, P2X4, P2X7
Abuse liability and safety (REMS)
Novel mechanisms of action for future pain therapies

Speakers at this year’s event include:

Jeffrey S. Mogil, Ph.D., E.P. Taylor Chair in Pain Studies, Canada Research Chair in Genetics of Pain, McGill University

William K. Schmidt, Ph.D., Vice President, CG Pharmaceuticals

Theodore Cicero, Ph.D., Professor of Psychiatry, Anatomy & Neurobiology, Washington University in St. Louis
David Hewitt, MD, Senior Director, Clinical Neuroscience, Merck & Co.

Gary W. Jay, MD, DAAPM, FAAPM, Senior Director, Clinical Disease Area Expert - Pain, Pfizer, Inc.

Lynn R. Webster, MD, FACPM, FASAM, Medical Director and Founder, Lifetree Clinical Research & Pain Clinic, Director-At-Large, American Academy of Pain Medicine

Dr. Luca Benatti, CEO, Newron

Andy Billinton, Ph.D., Behavioral and Translational Pharmacology Leader, Pain, Neurosciences, GlaxoSmithKline

Jennifer Bolen, JD, Founder, The Legal Side of Pain (A division of the J. Bolen Group, LLC)

Michael Gold, Ph.D., Associate Professor, Anesthesiology, University of Pittsburgh

James R. Gorman, MD, Ph.D., CEO and Chief Medical Officer, BioAssets Development Corporation

Hyungsuk Kim, DDS, Ph.D, Staff Scientist, NINR, National Institutes of Health

Jennifer Laird, Ph.D., Senior Principal Scientist, AstraZeneca R&D

Frédérique Menzaghi, Ph.D., Vice President Research & Development, Cara Therapeutics

Patricia Richards, MD, Ph.D., Chief Medical Officer, QRx Pharma

For the complete list of speakers as well as the agenda, please visit www.paintherapeuticsummit.com or call 1-312-244-3703.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4041724.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. FASEB Encourages NIGMS to Broaden Scientific Training Opportunities
2. Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Scientific breakthrough in genetic studies of animal domestication
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Japan Science and Technology Agency (JST) Selects Scopus Custom Data for Citation Linkage Analysis Between Scientific Articles and Patents
7. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
8. Boston Scientific Announces Completion of $2 Billion Senior Notes Offering
9. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
10. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
11. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):